Core Laboratories INC /DE/ 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NYSE
Core Laboratories Inc. reported a significant decrease in net income for Q2 2026 compared to the prior year, impacted by geopolitical conflicts and supply chain disruptions.
NYSE
Core Laboratories Inc. announced a 21% year-over-year increase in net income for Q3 2025, driven by operational efficiencies and international service demand, despite flat total revenue.
NYSE
Core Laboratories Inc. reported a significant sequential rebound in net income and revenue for the second quarter of 2025, despite flat year-over-year revenue and ongoing geopolitical and trade uncertainties.
NYSE
Core Laboratories' Q1 2025 results reflect a decrease in revenue and operating income, impacted by geopolitical conflicts and sanctions, though partially offset by growth in well completion diagnostic services.
NYSE
Core Laboratories Inc. announced its Q3 2024 results, showing a 7% increase in total revenue and a 27% increase in net income attributable to Core Laboratories Inc. compared to the same period last year.
NYSE
Core Laboratories Inc. reports a mixed second quarter with a slight revenue increase but a significant decrease in net income compared to the previous year.
NYSE
Core Laboratories Inc. saw a modest increase in revenue and improved profitability in the first quarter of 2024, driven by international growth and cost management.